A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis

Table 1

Nerve conduction study.

Nerve (right side)			Day of examination	Wrist or ankle latency, ms (amplitude)	Elbow or knee latency, ms (amplitude)	Velocity (m/s)
Median	Right	Motor	10	3.30 (16.7 mV)	6.93 (16.4 mV)	57.9
			38	3.39 (11.6 mV)	8.16 (2.7 mV)	45.0
		Sensory	10	2.64 (2.3 µV)	—	51.1
			38	2.98 (3.7 µV)	—	50.3
	Left	Motor	10	3.51 (3.9 mV)	7.32 (3.5 mV)	52.5
		Sensory	10	2.46 (4.3 µV)	—	64.2
Ulnar	Right	Motor	10	2.67 (7.7 mV)	7.32 (4.0 mV)	44.1
			38	2.76 (11.2 mV)	7.32 (10.9 mV)	54.2
		Sensory	10	2.30 (2.3 µV)	—	60.9
			38	2.42 (2.1 µV)	—	53.7
	Left	Motor	10	2.88 (0.10 mV)	8.07 (0.05 mV)	33.7
		Sensory	10	n.e.	—	—
Tibial	Right	Motor	10	4.30 (0.07 mV)	n.e.	—
Sural	Right	Sensory	10	n.e.	—	—

Day of examination, number of days since nivolumab administration; n.e., not evoked. Abnormal data are italicized.